Terms: = Prostate cancer AND PAX5, Q02548, 5079, ENSG00000196092, BSAP AND Treatment
18 results:
1. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
[TBL] [Abstract] [Full Text] [Related]
2. Phase I Study of Niraparib in Combination with Radium-223 for the treatment of Metastatic Castrate-Resistant prostate cancer.
Quinn Z; Leiby B; Sonpavde G; Choudhury AD; Sweeney C; Einstein D; Szmulewitz R; Sartor O; Knudsen K; Yang ES; Kelly WK
Clin Cancer Res; 2023 Jan; 29(1):50-59. PubMed ID: 36321991
[TBL] [Abstract] [Full Text] [Related]
3. Contrast enhanced ultrasound (CEUS) with parametric imaging after irreversible electroporation (IRE) of the prostate to assess the success of prostate cancer treatment.
Jung EM; Engel M; Wiggermann P; Schicho A; Lerchbaumer M; Stroszczynski C; Fischer T; Wiesinger I
Clin Hemorheol Microcirc; 2021; 77(3):303-310. PubMed ID: 33337354
[TBL] [Abstract] [Full Text] [Related]
4. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
5. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract] [Full Text] [Related]
6. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract] [Full Text] [Related]
7. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract] [Full Text] [Related]
8. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
[TBL] [Abstract] [Full Text] [Related]
9. Intravesical hemostatic gelatin matrix instillation in the management of intractable hematuria.
Margreiter M; Sharma V; Schauer I; Klingler HC
Urology; 2013 Sep; 82(3):724-8. PubMed ID: 23987168
[TBL] [Abstract] [Full Text] [Related]
10. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic and prognostic use of bone turnover markers.
Joerger M; Huober J
Recent Results Cancer Res; 2012; 192():197-223. PubMed ID: 22307377
[TBL] [Abstract] [Full Text] [Related]
12. Urban-rural differences in prostate cancer outcomes in Australia: what has changed?
Baade PD; Youlden DR; Coory MD; Gardiner RA; Chambers SK
Med J Aust; 2011 Mar; 194(6):293-6. PubMed ID: 21426283
[TBL] [Abstract] [Full Text] [Related]
13. Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy.
Linden RA; Weiner PR; Gomella LG; Dicker AP; Suh DB; Trabulsi EJ; Valicenti RK
Urology; 2009 Apr; 73(4):881-6. PubMed ID: 19193411
[TBL] [Abstract] [Full Text] [Related]
14. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
Coory MD; Baade PD
Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
[TBL] [Abstract] [Full Text] [Related]
15. International trends in prostate-cancer mortality: the decrease is continuing and spreading.
Baade PD; Coory MD; Aitken JF
Cancer Causes Control; 2004 Apr; 15(3):237-41. PubMed ID: 15090718
[TBL] [Abstract] [Full Text] [Related]
16. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
[TBL] [Abstract] [Full Text] [Related]
17. Population-based study of long-term survival in patients with clinically localised prostate cancer.
Lu-Yao GL; Yao SL
Lancet; 1997 Mar; 349(9056):906-10. PubMed ID: 9093251
[TBL] [Abstract] [Full Text] [Related]
18. [The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action].
Panteleeva ES; Sviridova TV; Neprina GS; Sirotkina NP
Urol Nefrol (Mosk); 1996; (1):28-31. PubMed ID: 8659039
[TBL] [Abstract] [Full Text] [Related]
